Global Atopic Dermatitis Drugs Market 2023-2027

Global Atopic Dermatitis Drugs Market 2023-2027
Technavio has been monitoring the atopic dermatitis drugs market and is forecast to grow by USD 4720.19 mn during 2022-2027, accelerating at a CAGR of 9.28% during the forecast period. Our report on the atopic dermatitis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of atopic dermatitis, increasing healthcare expenditure, and strong R&D pipeline.

Technavio's atopic dermatitis drugs market is segmented as below:

By Route of AdministrationOralTopicalInjectableBy Drug ClassBiologicsPDE4 inhibitorsCorticosteroidsCalcineurin inhibitorsBy GeographyNorth AmericaEuropeAsiaRest of World (ROW)This study identifies strategic partnerships and acquisitions as one of the prime reasons driving the atopic dermatitis drugs market growth during the next few years. Also, geopolitical uncertainties and programs to promote awareness of atopic dermatitis will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the atopic dermatitis drugs market covers the following areas:Atopic dermatitis drugs market sizingAtopic dermatitis drugs market forecastAtopic dermatitis drugs market industry analysisTechnavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading atopic dermatitis drugs market vendors that include AbbVie Inc., Arcutis Biotherapeutics Inc., Asana BioSciences LLC, Astellas Pharma Inc., Bausch Health Co. Inc., Bayer AG, Bristol Myers Squibb Co., Dermavant Sciences Inc., Eli Lilly and Co., Evelo Biosciences Inc., Galderma SA, Incyte Corp., LEO Pharma AS, Maruho Co. Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, Viatris Inc., and BiomX Inc. Also, the atopic dermatitis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.